IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer

C. N. Andreassen; J. G. Eriksen; K. Jensen; C. R. Hansen; B. S. Sørensen; P. Lassen; J. Alsner; L. M.H. Schack; J. Overgaard; C. Grau

doi:10.1016/j.oraloncology.2018.09.001

IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer

C. N. Andreassen^*, J. G. Eriksen, K. Jensen, C. R. Hansen, B. S. Sørensen, P. Lassen, J. Alsner, L. M.H. Schack, J. Overgaard, C. Grau

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

Radiotherapy (RT) is an integral component in the management of head and neck cancer. Despite progress in several respects, a noteworthy proportion of the treated patients do not achieve complete response after RT. Regardless of novel dose delivery technologies, RT for head and neck cancer is still associated with acute as well as late toxicity. These challenges could potentially be addressed by means of personalized treatment. In this paper, we discuss the possibilities for dose escalation, dose de-escalation and allocation to systemic concomitant treatment based on prognostic and predictive markers for tumor control as well as predictive markers for normal tissue radiosensitivity.

Originalsprog	Engelsk
Tidsskrift	Oral Oncology
Vol/bind	86
Sider (fra-til)	91-99
Antal sider	9
ISSN	1368-8375
DOI	https://doi.org/10.1016/j.oraloncology.2018.09.001
Status	Udgivet - 1 nov. 2018

Adgang til dokumentet

10.1016/j.oraloncology.2018.09.001

Andre filer og links

http://www.scopus.com/inward/record.url?scp=85053483801&partnerID=8YFLogxK

Citationsformater

@article{8fba50f9c34443109ccc8dd174184653,

title = "IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer",

abstract = "Radiotherapy (RT) is an integral component in the management of head and neck cancer. Despite progress in several respects, a noteworthy proportion of the treated patients do not achieve complete response after RT. Regardless of novel dose delivery technologies, RT for head and neck cancer is still associated with acute as well as late toxicity. These challenges could potentially be addressed by means of personalized treatment. In this paper, we discuss the possibilities for dose escalation, dose de-escalation and allocation to systemic concomitant treatment based on prognostic and predictive markers for tumor control as well as predictive markers for normal tissue radiosensitivity.",

keywords = "Cancer stem cells, Head and neck cancer, HPV, Hypoxia, p16, Personalized medicine, Radiogenomics, Radiotherapy, SNP",

author = "Andreassen, {C. N.} and Eriksen, {J. G.} and K. Jensen and Hansen, {C. R.} and S{\o}rensen, {B. S.} and P. Lassen and J. Alsner and Schack, {L. M.H.} and J. Overgaard and C. Grau",

year = "2018",

month = nov,

day = "1",

doi = "10.1016/j.oraloncology.2018.09.001",

language = "English",

volume = "86",

pages = "91--99",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Pergamon Press",

}

TY - JOUR

T1 - IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer

AU - Andreassen, C. N.

AU - Eriksen, J. G.

AU - Jensen, K.

AU - Hansen, C. R.

AU - Sørensen, B. S.

AU - Lassen, P.

AU - Alsner, J.

AU - Schack, L. M.H.

AU - Overgaard, J.

AU - Grau, C.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Radiotherapy (RT) is an integral component in the management of head and neck cancer. Despite progress in several respects, a noteworthy proportion of the treated patients do not achieve complete response after RT. Regardless of novel dose delivery technologies, RT for head and neck cancer is still associated with acute as well as late toxicity. These challenges could potentially be addressed by means of personalized treatment. In this paper, we discuss the possibilities for dose escalation, dose de-escalation and allocation to systemic concomitant treatment based on prognostic and predictive markers for tumor control as well as predictive markers for normal tissue radiosensitivity.

AB - Radiotherapy (RT) is an integral component in the management of head and neck cancer. Despite progress in several respects, a noteworthy proportion of the treated patients do not achieve complete response after RT. Regardless of novel dose delivery technologies, RT for head and neck cancer is still associated with acute as well as late toxicity. These challenges could potentially be addressed by means of personalized treatment. In this paper, we discuss the possibilities for dose escalation, dose de-escalation and allocation to systemic concomitant treatment based on prognostic and predictive markers for tumor control as well as predictive markers for normal tissue radiosensitivity.

KW - Cancer stem cells

KW - Head and neck cancer

KW - HPV

KW - Hypoxia

KW - p16

KW - Personalized medicine

KW - Radiogenomics

KW - Radiotherapy

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=85053483801&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2018.09.001

DO - 10.1016/j.oraloncology.2018.09.001

M3 - Journal article

C2 - 30409326

AN - SCOPUS:85053483801

SN - 1368-8375

VL - 86

SP - 91

EP - 99

JO - Oral Oncology

JF - Oral Oncology

ER -

IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater